Lumos Pharma, Inc. (LUMO) — Financial statements
Income statement, balance sheet, and cash flow for Lumos Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↑34.7% | 2↑562.2% | 0.23↑36.9% | 0.17↓82.1% | 0.94 | |
| Cost of Revenue | 0.00↓100.0% | 0.05 | 0.00 | 0.00↓100.0% | 0.04 | |
| Gross Profit | 2↑39.1% | 1↑540.9% | 0.23↑36.9% | 0.17↓81.3% | 0.90 | |
| Operating Expenses | ||||||
| R&D Expenses | 22↑23.7% | 18↑9.9% | 16↑76.5% | 9↓58.5% | 22 | |
| General & Administrative Expenses | 17↑5.5% | 16↑2.4% | 15↓11.2% | 17↓27.7% | 24 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑5.5% | 16↑2.4% | 15↓11.2% | 17↓27.7% | 24 | |
| Other Expenses | 0.00↓100.0% | 0.09↓66.2% | 0.27 | 0.00↑100.0% | -0.02 | |
| Operating Expenses | 39↑15.2% | 34↑6.3% | 32↑19.3% | 26↓42.5% | 46 | |
| Total Costs & Expenses | 39↑15.2% | 34↑6.3% | 32↑19.3% | 26↓42.5% | 46 | |
| Operating Results | ||||||
| Operating Income | -37↓14.3% | -32↓2.2% | -31↓19.2% | -26↑41.7% | -45 | |
| Depreciation & Amortization | 0.04↓10.2% | 0.05↓82.1% | 0.27↓53.3% | 0.58↑1478.4% | 0.04 | |
| EBITDA | -37↓14.3% | -32↓2.8% | -31↓21.0% | -26↓166.0% | -10 | |
| EBIT | -37↓14.3% | -32↓2.2% | -31↓19.2% | -26↓171.0% | -10 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑113.7% | 0.87↑7183.3% | 0.01↓94.0% | 0.20↑500.0% | -0.05 | |
| Interest Income | 2↑113.7% | 0.87↑7183.3% | 0.01↓94.0% | 0.20 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.05 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -35 | |
| Other Income / Expenses | 3↑164.4% | 0.97↑243.4% | 0.28↓95.8% | 7↓81.2% | 35 | |
| Income Before Tax | -34↓9.6% | -31↓0.0% | -31↓58.2% | -20↑54.3% | -43 | |
| Income Tax Expense | -0.03↓123.1% | -0.01↑98.0% | -0.64↑95.4% | -14↓116541.7% | 0.01 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↓9.6% | -31↓2.1% | -30↓437.3% | -6↑41.6% | -10 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↓9.6% | -31↓2.1% | -30↓437.3% | -6↑86.8% | -43 | |
| Bottom-Line Net Income | -34↓9.6% | -31↓2.1% | -30↓381.9% | -6↑50.5% | -13 | |
| EPS (Basic) | -4.18↓12.7% | -3.71↓1.6% | -3.65↓334.5% | -0.84↑91.9% | -10.39 | |
| EPS (Diluted) | -4.18↓12.7% | -3.71↓1.6% | -3.65↓334.5% | -0.84↑91.9% | -10.39 | |
| Weighted Average Shares | 8↓2.7% | 8↑0.5% | 8↑23.0% | 7↑63.7% | 4 | |
| Weighted Average Diluted Shares | 8↓2.7% | 8↑0.5% | 8↑23.0% | 7↑63.7% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.